Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

The novel CETP inhibitor, once tested for the now-defunct pathway of HDL raising, reduces LDL as well as Lp(a).